Advertisement

Indian Journal of Clinical Biochemistry

, Volume 25, Issue 3, pp 250–259 | Cite as

Matrix Metalloproteinases and Their Inhibitors: Correlation with Invasion and Metastasis in Oral Cancer

  • Ragini D. Singh
  • N. Haridas
  • Jayendra B. Patel
  • Franky D. Shah
  • Shilin N. Shukla
  • Pankaj M. Shah
  • Prabhudas S. PatelEmail author
Original Article

Abstract

Matrix metalloproteinases (MMPs) have been implicated in invasion and metastasis of various malignancies. The study evaluated a comprehensive profile of MMP-2 and MMP-9 and their inhibitors, tissue inhibitor of metalloproteinases-2 (TIMP-2) and tissue inhibitor of metalloproteinases-1 (TIMP-1), respectively in 50 controls and 75 patients with oral squamous cell carcinoma (OSCC). Blood samples from controls and patients as well as malignant and adjacent normal tissues from the patients were collected. The study examined pro, active and total forms of MMP-2 and MMP-9 using zymography. Enzyme-linked immunoassay (ELISA) and reverse transcription polymerase chain reaction were carried out to evaluate protein levels and mRNA expression; respectively, for the MMPs and TIMPs. Plasma pro, active and total MMP-2, MMP-9 as well as TIMP-1 and TIMP-2 levels were significantly higher in oral cancer patients as compared to the controls. mRNA expression of the MMPs and TIMPs was significantly higher in malignant tissues as compared to adjacent normal tissues. A significant positive correlation was observed between levels of proMMP-9 and active MMP-9 with differentiation, stage and infiltration. ProMMP-2 and active MMP-2 exhibited significant positive correlation with differentiation and lymph node involvement. The multivariate analysis of ELISA results revealed a significant positive correlation between MMP-2, TIMP-1 and TIMP-2 levels with lymph node involvement, stage and differentiation. The receiver operating characteristic curve (ROC) analysis showed that the levels of MMPs and TIMPs have significant discriminatory efficacy to differentiate between controls and patients. The results indicate that MMP-2, MMP-9, TIMP-1 and TIMP-2 have significant clinical usefulness for oral cancer patients. Zymographic analysis is a simple, cost effective, rapid and sensitive alternative assay.

Keywords

MMPs TIMPs Oral cancer Zymography Metastasis Invasion 

References

  1. 1.
    Cancer incidence in five continents, volumes I to IX. International Agency for Research on Cancer (IARC Scientific Publications), Lyon. 2009. http://www-dep.iarc.fr/. Accessed 6 Jan 2009.
  2. 2.
    Subramanian S, Sankaranarayanan R, Bapat B, Somanathan T, Thomas G, Mathew B, et al. Cost-effectiveness of oral cancer screening: results from a cluster randomized controlled trial in India. Bull World Health Organ. 2009;87:200–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Muwonge R, Ramadas K, Sankila R, Thara S, Thomas G, Vinoda J, et al. Role of tobacco chewing and alcohol drinking in the risk of oral cancer in Trivandrum, India: a nested case control design using incident cancer cases. Oral Oncol. 2008;44:446–54.CrossRefPubMedGoogle Scholar
  4. 4.
    Vicente JC, Fresno MF, Villalaín L, Vega JA, López-Arranz JS. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol. 2005;41:283–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Rocca GL, Minafra IP, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer. 2004;90:1414–21.CrossRefPubMedGoogle Scholar
  6. 6.
    Staack A, Badendieck S, Schnorr D, Loening SA, Jung K. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. 2006. http://www.biomedcentral.com/1471-2490/6/19. Accessed 10 Aug 2006.
  7. 7.
    Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 2005;83:287–97.CrossRefGoogle Scholar
  8. 8.
    Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H. Biomarkers in dysplasia of the oral cavity: a systematic review. Oral Oncol. 2009;45:647–53.CrossRefPubMedGoogle Scholar
  9. 9.
    O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2001;127:813–20.PubMedGoogle Scholar
  10. 10.
    Ranuncolo SM, Matos E, Loria D, Vilensky M, Rojo R, Bal de Kier Joffe E, et al. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer (Phila). 2002;94:1483–91.CrossRefGoogle Scholar
  11. 11.
    Lorenzo JA, Pilbeam CC, Kalinowski JF, Hibbs MS. Production of both 92 and 72 kDa gelatinases by bone cells. Matrix. 1992;12:282–90.PubMedGoogle Scholar
  12. 12.
    Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 2009;21:1323–33.PubMedGoogle Scholar
  13. 13.
    Hong Q, Jun T, Lei J, Xiling J, Tamamura R. Expression and clinical significance of matrix metalloproteinase-2 and its inhibitor TIMP-2 in oral squamous cell carcinoma. J Hard Tissue Biol. 2006;15:54–60.CrossRefGoogle Scholar
  14. 14.
    Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135–49.PubMedGoogle Scholar
  15. 15.
    Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res. 2004;10:3110–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinases and oral cancer. Oral Oncol. 1999;35:227–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Kawamata H, Uchida D, Hamano H, Kimura-Yanagawa T, Nakashiro KI, Hino S, et al. Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis. Int J Oncol. 1998;13:699–704.PubMedGoogle Scholar
  18. 18.
    Charous SJ, Stricklin GP, Nanney LB, Netterville JL, Burkey BB. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol. 1997;106:271–8.PubMedGoogle Scholar
  19. 19.
    Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A, et al. Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck. 1999;21:627–38.CrossRefPubMedGoogle Scholar
  20. 20.
    Ikebe T, Shinohara M, Takeuchi H, Beppu M, Kurahara S, Nakamura S, et al. Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clin Exp Metastasis. 1999;17:315–23.CrossRefPubMedGoogle Scholar
  21. 21.
    Miyajima Y, Nakano R, Morimatsu M. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol. 1995;104:678–84.PubMedGoogle Scholar
  22. 22.
    Overall CM, Kleifeld O. Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006;6:227–39.CrossRefPubMedGoogle Scholar
  23. 23.
    Kuropkat C, Plehn S, Herz U, Dunne AA, Renz H, Werner JA. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer. Anticancer Res. 2002;22:2221–7.PubMedGoogle Scholar
  24. 24.
    Riedel F, Gotte K, Schwalb J, Hormann K. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma. Anticancer Res. 2000;20:3045–9.PubMedGoogle Scholar
  25. 25.
    Sutinen M, Kainulainen T, Hursaiken T, Vesterlund E, Alexander JP, Overall CM, et al. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral premalignant lesions, oral squamous cell carcinoma and lymph node metastasis. Br J Cancer. 1998;77:2239–45.PubMedGoogle Scholar
  26. 26.
    Hong SD, Hong SP, Lee JI, Lim CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol. 2000;36:207–13.CrossRefPubMedGoogle Scholar
  27. 27.
    Tokumaru Y, Fujii M, Otani Y, Kameyama K, Imanishi Y, Igarashi N, et al. Activation of matrix metalloproteinase-2 in head and neck squamous cell carcinoma: studies of clinical sample and in vitro cell lines co-cultured with fibroblasts. Cancer Lett. 2000;150:15–21.CrossRefPubMedGoogle Scholar
  28. 28.
    Shah FD, Shukla SN, Shah PM, Shukla HK, Patel PS. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer. 2009;46:194–202.CrossRefPubMedGoogle Scholar
  29. 29.
    Patel BP, Shah PM, Rawal UM, Desai AA, Shah SV, Rawal RM, et al. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. J Surg Oncol. 2005;90:81–8.CrossRefPubMedGoogle Scholar
  30. 30.
    O-charoenrat P, Rhys-Evans P, Modjtahedi H, Court W, Box G, Eccles S. Over-expression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer. 2000;86:307–17.CrossRefPubMedGoogle Scholar
  31. 31.
    Ondruschka C, Buhtz P, Motsch C, Freigang B, Schneider-Stock R, Roessner A, et al. Prognostic value of MMP-2, -9 and TIMP-1, -2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res Pract. 2002;198:509–15.CrossRefPubMedGoogle Scholar
  32. 32.
    Yoshizaki T, Maruyama Y, Sato H, Furukawa M. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poorprognosis in tongue squamous cell carcinoma. Int J Cancer. 2001;95:44–50.CrossRefPubMedGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2010

Authors and Affiliations

  • Ragini D. Singh
    • 1
  • N. Haridas
    • 2
  • Jayendra B. Patel
    • 1
  • Franky D. Shah
    • 1
  • Shilin N. Shukla
    • 1
  • Pankaj M. Shah
    • 1
  • Prabhudas S. Patel
    • 1
    Email author
  1. 1.Biochemistry Research DivisionThe Gujarat Cancer and Research InstituteAsarwa, AhmedabadIndia
  2. 2.Pramukhswami Medical CollegeKaramsad, AnandIndia

Personalised recommendations